Govcap’s research team has delineated seven high-potential sectors within the rapidly expanding longevity market, using market size projections, CAGR data, and profiles of key players. Their analysis encompasses geroscience, regenerative medicine, AI in drug discovery, personalized wellness tech, AgeTech solutions, financial services for aging populations, and premium concierge clinics, equipping investors with actionable insights.
Key points
- Geroscience & senolytics: $4.13B to $6.39B market by 2030 (CAGR 7.6%), targeting cellular anti-aging interventions.
- Regenerative medicine & gene therapies: Projected growth from $168B to $249B by 2034 (CAGR 19.2%), driven by CRISPR and stem cell platforms.
- AI in longevity drug discovery: Market expansion from $1.48B to $15.5B by 2032 (CAGR ~29.9%), leveraging data-driven R&D acceleration and NVIDIA hardware.
Q&A
- What is geroscience?
- What are senolytics?
- How does CAGR relate to market projections?
- What is AgeTech?